/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

E

Erel Joffe

Memorial Sloan Kettering Cancer Center(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

141

Papers

2.4K

Citations

22

h-index

39

i10-index

Erel Joffe is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & CAR-T cell therapy research. The author has an h-index of 22, co-authored 120 publications.

ORCID: 0000-0002-7883-289X

Research Topics

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research CAR-T cell therapy research CNS Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders

Papers by this author

works

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

2021 · Blood Cancer Journal · 64 citations

https://doi.org/10.1038/s41408-021-00506-3

Sabela Bobillo Erel Joffe David Sermer Patrizia Mondello

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

2023 · Journal of Clinical Oncology · 42 citations

https://doi.org/10.1200/jco.23.00365

Katharine L. Lewis Lasse Hjort Jakobsen Diego Villa Karin E. Smedby

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

2018 · Blood Cancer Journal · 34 citations

https://doi.org/10.1038/s41408-018-0089-0

Andrew M. Intlekofer Erel Joffe Connie Lee Batlevi Patrick Hilden

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

2022 · Blood Cancer Journal · 5 citations

https://doi.org/10.1038/s41408-022-00620-w

Fushen Sha Michelle Okwali Anna Alperovich Philip Caron

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

2021 · Blood · 3 citations

https://doi.org/10.1182/blood-2021-154226

David Sermer Santosha A. Vardhana Erin Biggar Alison J. Moskowitz

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

2023 · Annals of Hematology · 3 citations

https://doi.org/10.1007/s00277-023-05321-3

Grzegorz S. Nowakowski Dok Hyun Yoon Patrizia Mondello Erel Joffe

Research topics

topics

Lymphoma Diagnosis and Treatment

Chronic Lymphocytic Leukemia Research

CAR-T cell therapy research

CNS Lymphoma Diagnosis and Treatment

Viral-associated cancers and disorders

Chat about Author

Papers

Chat

Click to start Chat